<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35106317</PMID><DateRevised><Year>2024</Year><Month>04</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement.</ArticleTitle><Pagination><StartPage>ofab640</StartPage><MedlinePgn>ofab640</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ofab640</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofab640</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is mounting evidence for the presence of postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC), but there is limited information on the spectrum, magnitude, duration, and patterns of these sequelae as well as their influence on quality of life.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We assembled a cohort of adults with a documented history of SARS-CoV-2 RNA positivity at&#x2005;&#x2265;2 weeks past onset of coronavirus disease 2019 (COVID-19) symptoms or, if asymptomatic, first positive test. At 4-month intervals, we queried physical and mental health symptoms and quality of life.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the first 179 participants enrolled, 10 were asymptomatic during the acute phase of SARS-CoV-2 infection, 125 were symptomatic but not hospitalized, and 44 were symptomatic and hospitalized. During the postacute phase, fatigue, shortness of breath, concentration problems, headaches, trouble sleeping, and anosmia/dysgeusia were most common through 8 months of observation. Symptoms were typically at least somewhat bothersome and sometimes exhibited a waxing-and-waning course. Some participants experienced symptoms of depression, anxiety, and post-traumatic stress, as well as difficulties with performance of usual activities. The median visual analogue scale rating of general health was lower at 4 and 8 months compared with pre-COVID-19. Two clusters of symptom domains were identified.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Many participants report bothersome symptoms following onset of COVID-19 with variable patterns of persistence and impact on quality of life. The substantial variability suggests the existence of multiple subphenotypes of PASC. A rigorous approach to the prospective measurement of symptoms and functional manifestations sets the stage for the next phase of research focusing on the pathophysiologic causes of the various subgroups of PASC.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peluso</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-0585-6230</Identifier><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>J Daniel</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Global Health Sciences, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>F.I. Proctor Foundation, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davidson</LastName><ForeName>Michelle C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathur</LastName><ForeName>Sujata</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durstenfeld</LastName><ForeName>Matthew S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spinelli</LastName><ForeName>Matthew A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoh</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tai</LastName><ForeName>Viva</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fehrman</LastName><ForeName>Emily A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Leonel</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Yanel</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Meghann C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arreguin</LastName><ForeName>Mireya I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngo</LastName><ForeName>Lynn H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deswal</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munter</LastName><ForeName>Sadie E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Enrique O</ForeName><Initials>EO</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anglin</LastName><ForeName>Khamal A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romero</LastName><ForeName>Mariela D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavs</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rugart</LastName><ForeName>Paulina R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jessica Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sans</LastName><ForeName>Hannah M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Victoria W</ForeName><Initials>VW</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellis</LastName><ForeName>Payton K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donohue</LastName><ForeName>Kevin C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massachi</LastName><ForeName>Jonathan A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Jacob O</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehdi</LastName><ForeName>Irum</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pineda-Ramirez</LastName><ForeName>Jesus</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Alex F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wenger</LastName><ForeName>Megan A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assenzio</LastName><ForeName>Melissa T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krone</LastName><ForeName>Melissa R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutishauser</LastName><ForeName>Rachel L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Barraquer</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenhouse</LastName><ForeName>Bryan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sauceda</LastName><ForeName>John A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Center for AIDS Prevention Studies, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gandhi</LastName><ForeName>Monica</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7025-1994</Identifier><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheffler</LastName><ForeName>Aaron Wolfe</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsue</LastName><ForeName>Priscilla Y</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henrich</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deeks</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Jeffrey N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI158013</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AI060530</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AI076614</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI167648</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 HL143961</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HL007731</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI141003</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AI147159</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AI144048</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AI157875</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AI126521</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AI146268</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2021 Mar 12:2021.03.11.21252311. doi: 10.1101/2021.03.11.21252311</RefSource><PMID Version="1">33758895</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of SARS-CoV-2 (PASC)</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>2</Day><Hour>5</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35106317</ArticleId><ArticleId IdType="pmc">PMC8755302</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofab640</ArticleId><ArticleId IdType="pii">ofab640</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guan W-J, Ni Z-Y, Hu Y, et al. . Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382:1708&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal P, Choi JJ, Pinheiro LC, et al. . Clinical characteristics of Covid-19 in New York City. N Engl J Med 2020; 382:2372&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7182018</ArticleId><ArticleId IdType="pubmed">32302078</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M, et al. . Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020; 323:2052&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177629</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>
Harding L.
&#x201c;Weird as hell&#x201d;: the Covid-19 patients who have symptoms for months.
Guardian. 15 May 2020. Available at: http://www.theguardian.com/world/2020/may/15/weird-hell-professor-advent-calendar-covid-19-symptoms-paul-garner. Accessed 7 March 2021.</Citation></Reference><Reference><Citation>
Chuck E, Edwards E.. 
Doctors couldn&#x2019;t help these COVID-19 patients with their endless symptoms. So they turned to one another.
NBC News. 17 May 2020. Available at: https://www.nbcnews.com/health/health-news/doctors-couldn-t-help-these-covid-19-patients-their-endless-n1208116. Accessed 7 March 2021.</Citation></Reference><Reference><Citation>
Horowitz J.
Surviving Covid-19 may not feel like recovery for some.
New York Times. 10 May 2020. Available at: https://www.nytimes.com/2020/05/10/world/europe/coronavirus-italy-recovery.html. Accessed 7 March 2021.</Citation></Reference><Reference><Citation>
Yong E.
COVID-19 can last for several months.
The Atlantic. 4 June 2020. Available at: https://www.theatlantic.com/health/archive/2020/06/covid-19-coronavirus-longterm-symptoms-months/612679/. Accessed 7 March 2021.</Citation></Reference><Reference><Citation>
Yong E.
Long-haulers are redefining COVID-19.
The Atlantic. 19 August 2020. Available at: https://www.theatlantic.com/health/archive/2020/08/long-haulers-covid-19-recognition-support-groups-symptoms/615382/. Accessed 7 March 2021.</Citation></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021; 38:101019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 2020; 324:603&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. . 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397:220&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Kim SS, Lindsell CJ, et al. . Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, March-June 2020. MMWR Morb Mortal Wkly Rep 2020; 69:993&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JBW.. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002; 64:258&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">11914441</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin R, Charro F de.. EQ-SD: a measure of health status from the EuroQol group. Ann Med 2001; 33:337&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">11491192</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer RL, Kroenke K, Williams JBW, L&#xf6;we B.. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166:1092&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16717171</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Strine TW, Spitzer RL, Williams JBW, Berry JT, Mokdad AH.. The PHQ-8 as a measure of current depression in the general population. J Affect Disord 2009; 114:163&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">18752852</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron RP, Gusman D.. The Primary Care PTSD Screen (PC-PTSD): development and operating characteristics. Primary Care Psychiatr 2003; 9:9&#x2013;14.</Citation></Reference><Reference><Citation>Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL.. The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): development and initial psychometric evaluation: Posttraumatic Stress Disorder Checklist for DSM-5. J Trauma Stress 2015; 28:489&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">26606250</ArticleId></ArticleIdList></Reference><Reference><Citation>Price M, Szafranski DD, van Stolk-Cooke K, Gros DF.. Investigation of abbreviated 4 and 8 item versions of the PTSD Checklist 5. Psychiatry Res 2016; 239:124&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">27137973</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthieu M, Mohammed S.. Variable selection for model-based clustering using the integrated complete-data likelihood. Stat Comput 2015; 27:1049&#x2013;63.</Citation></Reference><Reference><Citation>Marbac M, Sedki M.. VarSelLCM: an R/C++ package for variable selection in model-based clustering of mixed-data with missing values. Bioinformatics 2019; 35:1255&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">30192923</ArticleId></ArticleIdList></Reference><Reference><Citation>Matta J, Wiernik E, Robineau O, et al. . Association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms among French adults during the COVID-19 pandemic. JAMA Intern Med 2022; 182:19&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8576624</ArticleId><ArticleId IdType="pubmed">34747982</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Lee KA, Lochlainn MN, et al. . Symptom clusters in COVID-19: a potential clinical prediction tool from the COVID symptom study app. Sci Adv. In press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7978420</ArticleId><ArticleId IdType="pubmed">33741586</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster AJ, Gaitskell K, Turnbull I, et al. . Characterisation, identification, clustering, and classification of disease. Sci Rep 2021; 11:5405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7940639</ArticleId><ArticleId IdType="pubmed">33686097</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng S, Fan J, Yu F, et al. . Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ 2020; 369:m1443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190077</ArticleId><ArticleId IdType="pubmed">32317267</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, et al. . Evolution of antibody immunity to SARS-CoV-2. Nature 2021; 591:639&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C, Wong P, Klein J, et al. . Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 2020; 584:463&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Laing AG, Lorenc A, del Molino del Barrio I, et al. . A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med 2020; 26:1623&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">32807934</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Lu S, Tang AF, et al. . Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. In press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Giron LB, Dweep H, Yin X, et al. . Severe COVID-19 is fueled by disrupted gut barrier integrity. bioRxiv 2020.11.13.20231209 [Preprint]. 16 November 2020. Available at: 10.1101/2020.11.13.20231209. Accessed 1 September 2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.11.13.20231209</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann VO, Carerj ML, Wieters I, et al. . Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; 5:1265&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7385689</ArticleId><ArticleId IdType="pubmed">32730619</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Zhao P, Tang D, et al. . Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging. JACC Cardiovasc Imaging 2020; 13:2330&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7214335</ArticleId><ArticleId IdType="pubmed">32763118</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y, Estes SK, Ali RA, et al. . Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med 2020; 12:eabd3876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7724273</ArticleId><ArticleId IdType="pubmed">33139519</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu SX, Tyagi T, Jain K, et al. . Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nat Rev 2021; 18:194&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7675396</ArticleId><ArticleId IdType="pubmed">33214651</ArticleId></ArticleIdList></Reference><Reference><Citation>Goshua G, Pine AB, Meizlish ML, et al. . Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol 2020; 7:e575&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7326446</ArticleId><ArticleId IdType="pubmed">32619411</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch A, Dupont A, Goutay J, et al. . Endotheliopathy is induced by plasma from critically ill patients and associated with organ failure in severe COVID-19. Circulation 2020; 142:1881&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7643783</ArticleId><ArticleId IdType="pubmed">32970476</ArticleId></ArticleIdList></Reference><Reference><Citation>Maccio U, Zinkernagel AS, Shambat SM, et al. . SARS-CoV-2 leads to a small vessel endotheliitis in the heart. EBioMedicine 2021; 63:103182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7808909</ArticleId><ArticleId IdType="pubmed">33422990</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z, Flammer AJ, Steiger P, et al. . Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395:1417&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SE, Feng A, Meng W, et al. . New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun 2021; 12:5417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Han T, Chen J, et al. . Clinical and autoimmune characteristics of severe and critical cases of COVID-19. Clin Transl Sci 2020; 13:1077&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264560</ArticleId><ArticleId IdType="pubmed">32315487</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhadelia N, Belkina AC, Olson A, et al. . Distinct autoimmune antibody signatures between hospitalized acute COVID-19 patients, SARS-CoV-2 convalescent individuals, and unexposed pre-pandemic controls. bioRxiv 2021.01.21.21249176 [Preprint]. 25 January 2021. Available at: 10.1101/2021.01.21.21249176. Accessed 1 September 2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.21.21249176</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E, Bartley CM, Chow RD, et al. . Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. Cell Rep Med 2021; 2:100288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8091032</ArticleId><ArticleId IdType="pubmed">33969321</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue JK, Franko NM, McCulloch DJ, et al. . Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open 2021; 4:e210830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson KB, Rao M, Bonilla H, et al. . Patients with uncomplicated COVID-19 have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic. Clin Infect Dis 2021; 73:e826&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7929039</ArticleId><ArticleId IdType="pubmed">33624010</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellmuth J, Barnett TA, Asken BM, et al. . Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients. J Neurovirol 2021; 27:191&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7852463</ArticleId><ArticleId IdType="pubmed">33528824</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B, Mohn KG-I, Brokstad KA, et al. . Long COVID in a prospective cohort of home-isolated patients. Nat Med 2021; 27:1607&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>
Ayoubkhani D.
Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK - Office for National Statistics.
2021. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021. Accessed 7 April 2021.</Citation></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B.. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 2021; 594:259&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deitchman AN, Torres L, et al. . Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep 2021; 36:109518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Takahashi S, Hakim J, et al. . SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Sci Adv 2021; 7:eabh3409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8324059</ArticleId><ArticleId IdType="pubmed">34330709</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Thomas IJ, Munter SE, Deeks SG, Henrich TJ.. Lack of antinuclear antibodies in convalescent COVID-19 patients with persistent symptoms. Clin Infect Dis 2021;ciab890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9187313</ArticleId><ArticleId IdType="pubmed">34617982</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Munter SE, Lynch KL, et al. . Discordant virus-specific antibody levels, antibody neutralization capacity, and T-cell responses following 3 doses of SARS-CoV-2 vaccination in a patient with connective tissue disease. Open Forum Infect Dis 2021; 8:XXX&#x2013;XX.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8344490</ArticleId><ArticleId IdType="pubmed">34395717</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Sans HM, Forman CA, et al. . Plasma markers of neurologic injury and systemic inflammation in individuals with self-reported neurologic post-acute sequelae of SARS-CoV-2 infection (PASC). bioRxiv 2021.11.02.21265778 [Preprint]. 4 November 2021. Available at: 10.1101/2021.11.02.21265778. Accessed 15 November 2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.11.02.21265778</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld MS, Peluso MJ, Daniel Kelly J, et al. . Role of antibodies, inflammatory markers, and echocardiographic findings in post-acute cardiopulmonary symptoms after SARS-CoV-2 infection. medRxiv 2021.11.24.21266834 [Preprint]. 26 November 2021. Available at: 10.1101/2021.11.24.21266834. Accessed 1 December 2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.11.24.21266834</ArticleId><ArticleId IdType="pmc">PMC9220849</ArticleId><ArticleId IdType="pubmed">35389890</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>